Home infusion for myeloma drug passes early safety check

NCT ID NCT05041933

Completed Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see if the process followed safety rules without errors. If it works, this model could make treatment more convenient for patients and reduce hospital burden.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib (a chemotherapy drug given as a short intravenous infusion)
What this could lead to: If successful, this could show that giving certain chemotherapy infusions at home is safe and practical, potentially improving patient quality of life and reducing hospital visits.
What could go wrong: This is a very small pilot study (17 people) that only looked at whether the process works without errors. It does not test if the drug itself is effective or safe, and results may not apply to other drugs or regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL DISEASES

Contacts and locations

Locations

Limoges Hospital

Limoges, 87 042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.